Inovio Pharmaceuticals, Inc.
INOInovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).
Drugs in Pipeline
7
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Sep 3, 2026
22wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
VGX-3100
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
INO-4700
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
INO-3107
Respiratory Papillomatosis
INO-5401
Glioblastoma
INO-3112
Head and Neck Squamous Cell Cancer
INO-9012
Urothelial Carcinoma
VGX 3100
Cervical Intraepithelial Neoplasia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VGX-3100 | Phase 3 | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | - | - |
INO-4700 | Phase 2 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | - | - |
INO-3107 | Phase 2 | Respiratory Papillomatosis | - | - |
INO-5401 | Phase 2 | Glioblastoma | - | - |
INO-3112 | Phase 2 | Head and Neck Squamous Cell Cancer | - | - |
INO-9012 | Phase 2 | Urothelial Carcinoma | - | - |
VGX 3100 | Phase 2 | Cervical Intraepithelial Neoplasia | - | - |